Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. (NASDAQ: AEMD) is a clinical-stage medical device innovator advancing the Hemopurifier® - a therapeutic filtration device targeting cancer-enabling exosomes and life-threatening viruses. This page provides investors and medical professionals with essential updates on clinical developments, regulatory progress, and strategic initiatives.
Key resources include press releases detailing trial protocols, ethics committee approvals, and operational milestones. Users will find verified information on oncology applications for treatment-resistant cancers and infectious disease programs, all presented in compliance with financial disclosure standards.
Content highlights encompass FDA communications, trial enrollment updates, and peer-reviewed research collaborations. The curated news collection serves as a reliable reference for tracking the Hemopurifier®'s progress through clinical validation stages and potential therapeutic applications.
Bookmark this page for direct access to Aethlon Medical's official announcements, including breakthrough device designations and international trial expansions. Check regularly for updates on this pioneering approach to blood filtration technology and its implications for cancer immunotherapy advancement.
Aethlon Medical (Nasdaq: AEMD) reported financial results for Q4 FY2025 and provided corporate updates. Key highlights include treatment of three patients in the Hemopurifier® cancer trial in Australia, regulatory approval in India, and significant operational cost reductions. The company's cash balance stood at $5.5 million as of March 31, 2025.
Operating expenses decreased by 26% to $9.3 million from $12.6 million year-over-year. Preclinical data showed 98.5% removal of platelet-derived EVs in simulated Hemopurifier® treatment. The company is expanding research into Long COVID applications through collaboration with UCSF, addressing a market affecting 44-48 million people in the US.
Aethlon Medical (NASDAQ: AEMD) has published preclinical study results in Transplant Immunology demonstrating new potential applications for its Hemopurifier® blood filtration system in organ transplantation. The study, published February 28, 2025, shows the device's effectiveness in removing harmful extracellular vesicles (EVs) and microRNAs from renal perfusates of discarded donor kidneys.
The research indicates significant reductions in EVs and microRNAs linked to renal dysfunction, suggesting potential benefits for kidney transplant outcomes. This expands the Hemopurifier's therapeutic potential beyond its current applications in virology and oncology, presenting what the company calls a "pipeline within a device."
While the company's primary focus remains on Australian and India Oncology trials, these findings suggest the technology could potentially be integrated with existing organ preservation systems, though further evaluation and clinical trials would be necessary.
Aethlon Medical (NASDAQ: AEMD), a medical therapeutic company developing products for cancer and life-threatening infectious diseases, will present at the Emerging Growth Conference on February 19, 2025. The company's CEO, James Frakes, will deliver a 30-minute presentation starting at 11:25 AM Eastern time.
This interactive online event offers shareholders and the investment community the opportunity to engage directly with Mr. Frakes in real-time. Participants can submit questions in advance to Questions@EmergingGrowth.com or during the live session.
For those unable to attend live, an archived webcast will be available on EmergingGrowth.com and the Emerging Growth YouTube Channel. Registration is required through the provided webcast link to attend and receive updates.
Aethlon Medical (NASDAQ: AEMD) reported its fiscal Q3 2024 results and key developments. The company achieved a significant milestone with the first patient treated in their Hemopurifier® cancer trial in Australia on January 29, 2025. The treatment was completed successfully with no device-related complications.
The company implemented protocol modifications to improve trial efficiency, including changes to patient enrollment criteria and broadening eligibility requirements. Two clinical sites are currently active in Australia, with a third site expected to activate in February 2025.
Financial highlights include a cash balance of $4.8 million as of December 31, 2024. Operating expenses decreased by 50% to $1.8 million compared to $3.6 million in the same quarter last year, primarily due to reduced payroll expenses, professional fees, and general administrative costs. Net loss decreased to $1.8 million from $3.5 million in the prior year period.
Aethlon Medical (Nasdaq: AEMD), a medical therapeutic company developing products for cancer and infectious diseases treatment, has scheduled its fiscal third quarter financial results release for February 12, 2025, at 4:15 p.m. ET.
The company will host a conference call at 4:30 p.m. ET on the same day, featuring management's formal remarks followed by a Q&A session. The call will be accessible through pre-registration or direct dial-in, with replay available until March 12, 2025.
Aethlon Medical (NASDAQ: AEMD) has achieved a significant milestone by treating the first patient with its Hemopurifier device in an Australian clinical trial. The trial focuses on patients with solid tumors who show stable or progressive disease during anti-PD-1 monotherapy treatments like Keytruda® or Opdivo®.
The first patient, who showed disease progression after two months of Nivolumab treatment, received a 4-hour Hemopurifier treatment on January 29, 2025, at the Royal Adelaide Hospital, tolerating the procedure without complications. The trial aims to enroll approximately 18 patients to assess safety, feasibility, and optimal dosing.
The Hemopurifier is designed to remove tumor-derived extracellular vesicles (EVs) from the bloodstream, potentially improving response rates to anti-PD-1 therapies, which currently only benefit 30-40% of patients. The study will evaluate different treatment intervals and analyze changes in EV concentrations to inform future Premarket Approval studies.